Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee OsteoarthritisGlobeNewsWire • 04/16/24
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with SepsisGlobeNewsWire • 04/11/24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With SepsisGlobeNewsWire • 04/11/24
Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVAccesswire • 03/22/24
Enlivex Receives Regulatory Authorization From Israel's Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee OsteoarthritisAccesswire • 02/26/24
Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US HospitalsAccesswire • 02/21/24
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee OsteoarthritisGlobeNewsWire • 01/17/24
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With SepsisGlobeNewsWire • 12/20/23
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With SepsisGlobeNewsWire • 07/31/23
Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene TherapyGlobeNewsWire • 05/31/23
Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell TherapyGlobeNewsWire • 05/08/23
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell TherapyGlobeNewsWire • 04/19/23
Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical TrialsAccesswire • 04/14/23
Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid TumorsAccesswire • 04/12/23
Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business UpdatesGlobeNewsWire • 04/04/23
Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid TumorsGlobeNewsWire • 04/03/23
Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancersGlobeNewsWire • 03/20/23
Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRSGlobeNewsWire • 02/15/23
Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid TumorsGlobeNewsWire • 01/25/23